Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening - A prospective study

被引:14
作者
Benattar, C [1 ]
Audibert, F [1 ]
Taieb, J [1 ]
Ville, Y [1 ]
Roberto, A [1 ]
Lindenbaum, A [1 ]
Frydman, R [1 ]
机构
[1] Antoine Beclere Hosp, Biochem & Hormonol Lab, F-92141 Clamart, France
关键词
Down's syndrome; biochemical markers; antenatal screening; nuchal translucency; ultrasound markers; trisomy;
D O I
10.1159/000020900
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the sequential combination of ultrasound screening for fetal aneuploidy at 11-14 weeks with maternal biochemistry at 12-14 and 15-18 weeks of gestation. Methods: A prospective study including 1,656 women, with a singleton pregnancy booked before 13 weeks of gestation. Nuchal translucency (NT) thickness was measured by transabdominal ultrasound examination. a-fetoprotein, free beta hCG and hCG were measured by immunoradiometric (12-14 weeks) or immunometric (15-18 weeks) assays. Derived risks were then calculated. Cutoff risks were chosen first arbitrarily at 1/250 and then adjusted for a 5% false-positive rate. Results: Seven fetal aneuploidies were diagnosed, including 5 Down's syndromes, 1 trisomy 18 and 1 triploidy. Three Down's syndromes had concordant high risk with the 3 screenings. One was at low risk with NT, and another was at low risk by maternal serum screening, but sequential combination of screenings led to a 100% detection rate with cutoffs of 1/240, 1/160 and 1/250 for NT, first- and second-trimester biochemistry, respectively (i.e. for a cutoff adjusted for a 5% false-positive rate). Conclusion: This preliminary study suggests a benefit in combining maternal age-related risk together with NT and biochemical markers in the first or the second trimester. The algorithm combining these risks needs to be established in a wide population.
引用
收藏
页码:112 / 117
页数:6
相关论文
共 23 条
[1]   1ST-TRIMESTER BIOCHEMICAL SCREENING FOR FETAL CHROMOSOME-ABNORMALITIES AND NEURAL-TUBE DEFECTS [J].
AITKEN, DA ;
MCCAW, G ;
CROSSLEY, JA ;
BERRY, E ;
CONNOR, JM ;
SPENCER, K ;
MACRI, JN .
PRENATAL DIAGNOSIS, 1993, 13 (08) :681-689
[2]  
Ayme S, 1996, M S-MED SCI, V12, P393
[3]   ANALYSIS OF MATERNAL SERUM ALPHA-FETOPROTEIN AND FREE BETA-HUMAN CHORIONIC-GONADOTROPIN IN THE FIRST TRIMESTER - IMPLICATIONS FOR DOWNS-SYNDROME SCREENING [J].
BERRY, E ;
AITKEN, DA ;
CROSSLEY, JA ;
MACRI, JN ;
CONNOR, JM .
PRENATAL DIAGNOSIS, 1995, 15 (06) :555-565
[4]   ABNORMAL MATERNAL SERUM CHORIONIC-GONADOTROPIN LEVELS IN PREGNANCIES WITH FETAL CHROMOSOME-ABNORMALITIES [J].
BOGART, MH ;
PANDIAN, MR ;
JONES, OW .
PRENATAL DIAGNOSIS, 1987, 7 (09) :623-630
[5]   MATERNAL SERUM HCG AND FETAL NUCHAL TRANSLUCENCY THICKNESS FOR THE PREDICTION OF FETAL TRISOMIES IN THE FIRST TRIMESTER OF PREGNANCY [J].
BRIZOT, ML ;
SNIJDERS, RJM ;
BUTLER, J ;
BERSINGER, NA ;
NICOLAIDES, KH .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1995, 102 (02) :127-132
[6]  
CUCKLE HS, 1984, LANCET, V1, P926
[7]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[8]   SERUM PAPP-A MEASUREMENTS IN 1ST-TRIMESTER SCREENING FOR DOWN-SYNDROME [J].
HURLEY, PA ;
WARD, RHT ;
TEISNER, B ;
ILES, RK ;
LUCAS, M ;
GRUDZINSKAS, JG .
PRENATAL DIAGNOSIS, 1993, 13 (10) :903-908
[9]  
Kornman LH, 1996, PRENATAL DIAG, V16, P797, DOI 10.1002/(SICI)1097-0223(199609)16:9<797::AID-PD948>3.3.CO
[10]  
2-D